Osteoarthritis pain Therapeutic and Drug Pipeline Review H2

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Osteoarthritis Pain – Pipeline Review, H2 2017”.

Summary

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. If the condition worsens, it leads to rubbing of the bones against each other causing even more pain and loss of movement. Risk factors are age, joint injury, obesity and heredity. Treatment includes weight control, exercise and medications.

 

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

                                                                   

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385312-osteoarthritis-pain-pipeline-review-h2-2017       

 

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 23, 9, 1, 23, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

 

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)

 

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 

Table of Content: Key Points

Table of Contents 2

Introduction 5

Osteoarthritis Pain – Overview 6

Osteoarthritis Pain – Therapeutics Development 7

Osteoarthritis Pain – Therapeutics Assessment 18

Osteoarthritis Pain – Companies Involved in Therapeutics Development 28

Osteoarthritis Pain – Drug Profiles 46

Osteoarthritis Pain – Dormant Projects 201

Osteoarthritis Pain – Discontinued Products 205

Osteoarthritis Pain – Product Development Milestones 207

…Continued        

 

ACCESS REPORT @https://www.wiseguyreports.com/reports/2385312-osteoarthritis-pain-pipeline-review-h2-2017       

 

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports                                                                  

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts    

Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: sales@wiseguyreports.com
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com